{
  "symbol": "CALC",
  "company_name": "Calcimedica Inc",
  "ir_website": "https://ir.calcimedica.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "CalciMedica Announces Presentations at Upcoming Medical Meetings",
          "url": "https://ir.calcimedica.com/news-releases/news-release-details/calcimedica-announces-presentations-upcoming-medical-meetings",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![CalciMedica, Inc. Logo](/sites/g/files/knoqqb85191/themes/site/client_site/dist/images/Logo_Calcimedica_2023_June_500px.png) ](https://calcimedica.com \"CalciMedica\")\n\n  * [Technologies & Pipeline](https://calcimedica.com/technologies-pipeline/)\n  * [Pancreas](https://calcimedica.com/pancreas/)\n  * [Kidney](https://calcimedica.com/kidney/)\n  * [Lung](https://calcimedica.com/lung/)\n  * [About Us](https://calcimedica.com/about-us/)\n  * [Publications](https://calcimedica.com/publications/)\n  * [Investors + Media]()\n    * [Overview](/investor-relations)\n    * [News and Events](/news-events/press-releases)\n    * [Presentation](/presentations)\n    * [Corporate Governance](/corporate-governance/board-document-charters)\n    * [Stock Information](/stock-information/stock-quote-chart)\n    * [Financials and Filings](/financials-filings/sec-filings)\n    * [Resources](/resources/email-alerts)\n\n\n\n  * [Technologies & Pipeline](https://calcimedica.com/technologies-pipeline/)\n    * [Our Technologies](https://calcimedica.com/technologies-pipeline/#our-technologies)\n    * [Our Pipeline](https://calcimedica.com/technologies-pipeline/#our-pipeline)\n    * [Clinical Trials](https://calcimedica.com/technologies-pipeline/#clinical-trials)\n  * [Pancreas](https://calcimedica.com/pancreas/)\n    * [Acute Pancreatitis](https://calcimedica.com/pancreas/#acute-pancreatitis)\n      * [AP with SIRS](https://calcimedica.com/pancreas/#acute-pancreatitis-with-sirs)\n      * [Asparaginase-Induced Pancreatic Toxicity (AIPT)](https://calcimedica.com/pancreas/#asparaginase-induced-pancreatic-toxicity)\n    * [Chronic Pancreatitis](https://calcimedica.com/pancreas/#chronic-pancreatitis)\n  * [Kidney](https://calcimedica.com/kidney/)\n  * [Lung](https://calcimedica.com/lung/)\n\n\n\n  * [About Us](https://calcimedica.com/about-us/)\n  * [Publications](https://calcimedica.com/publications/)\n  * [Investors + Media]()\n    * [Overview](/investor-relations)\n    * [News and Events](/news-events/press-releases)\n    * [Presentation](/presentations)\n    * [Corporate Governance](/corporate-governance/board-document-charters)\n    * [Stock Information](/stock-information/stock-quote-chart)\n    * [Financials and Filings](/financials-filings/sec-filings)\n    * [Resources](/resources/email-alerts)\n  * [Contact Us](https://calcimedica.com/contact-us/)\n\n\n\n[ ](https://www.linkedin.com/company/calcimedica) [ ](https://twitter.com/calcimedicainc?lang=en)\n\nInvestor Relations \n\n#  Press Release \n\n[Press Releases](/news-events/press-releases)\n\n[IR Events & Presentations](/news-events/events-presentations)\n\n[Medical Events & Presentations](/news-events/medical-events-publications)\n\n## \n\nCalciMedica Announces Presentations at Upcoming Medical Meetings\n\nNovember 20, 2024\n\n[PDF Version](/node/8851/pdf)\n\n_Prof. Robert Sutton to_ _deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting_\n\n_Poster presentation on_ _Phase 2b CARPO trial_ _at Emergencies in Medicine (EIM) 2024 Meeting_\n\nLA JOLLA, Calif., Nov. 20, 2024 /PRNewswire/ -- CalciMedica Inc. (\"CalciMedica\") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for plenary presentation at the American Pancreatic Association (APA) 2024 Annual Meeting being held December 9-10 in Maui, HI, and the acceptance of an abstract for poster presentation at the Emergencies in Medicine (EIM) 2024 Meeting being held December 8-13 in Maui, HI.\n\n[ ![CalciMedica Logo \\(PRNewsfoto/CalciMedica, Inc.\\)](https://mma.prnewswire.com/media/685404/calcimedica_v3.jpg) ](https://mma.prnewswire.com/media/685404/calcimedica_v3.html)\n\nDetails for the presentations are as follows:\n\n**_Plenary Presentation at APA 2024 Annual Meeting_**\n\n**Presentation Title:** Auxora Decreases the Development of Severe Organ Failure in Patients with Acute Pancreatitis and SIRS\n\n**Presenter:** Prof. Robert Sutton, B.A. (Hons), M.B., B.S., D.Phil., FRCS, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust\n\n**Session Title:** Abstract Session 2 – Pancreatitis \n\n**Session Date and Time:** Tuesday, December 10, 8:00-9:30 a.m. HST\n\n**_Poster Presentation at EIM 2024 Meeting_**\n\n**Presentation Title:** A Randomized, Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in Patients with Acute Pancreatitis (AP) and Accompanying Systemic Inflammatory Response Syndrome (SIRS)- CARPO (NCT0468106)\n\nThe presentation and poster will be available following the sessions on the Medical Events & Presentations section of CalciMedica's IR website at [https://ir.calcimedica.com/news-events/medical-events-publications](https://c212.net/c/link/?t=0&l=en&o=4308358-1&h=3700785006&u=https%3A%2F%2Fir.calcimedica.com%2Fnews-events%2Fmedical-events-publications&a=https%3A%2F%2Fir.calcimedica.com%2Fnews-events%2Fmedical-events-publications).\n\n**About CalciMedica**CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – [NCT04681066](https://c212.net/c/link/?t=0&l=en&o=4308358-1&h=4058078610&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D2669185696%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D1699697110%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fstudy%25252FNCT04681066%25253Fterm%25253DNCT04681066%252526rank%25253D1%2526a%253DNCT04681066%26a%3DNCT04681066&a=NCT04681066)) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and completed a Phase 2 trial (called CARDEA – [NCT04345614](https://c212.net/c/link/?t=0&l=en&o=4308358-1&h=3693319698&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D3152801644%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D1827566996%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4206849-1%252526h%25253D575802973%252526u%25253Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fstudy%2525252FNCT04345614%252526a%25253DNCT04345614%2526a%253DNCT04345614%26a%3DNCT04345614&a=NCT04345614)) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – [NCT06374797](https://c212.net/c/link/?t=0&l=en&o=4308358-1&h=2491124280&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D2144183414%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D78069076%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fstudy%25252FNCT06374797%25253Fterm%25253DKOURAGE%252526rank%25253D1%2526a%253DNCT06374797%26a%3DNCT06374797&a=NCT06374797)) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – [NCT04195347](https://c212.net/c/link/?t=0&l=en&o=4308358-1&h=3071175575&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D1916833438%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D2087960553%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4206849-1%252526h%25253D3497808046%252526u%25253Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fstudy%2525252FNCT04195347%2525253Fterm%2525253DNCT04195347%25252526rank%2525253D1%252526a%25253DNCT04195347%2526a%253DNCT04195347%26a%3DNCT04195347&a=NCT04195347)) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit [www.calcimedica.com](https://c212.net/c/link/?t=0&l=en&o=4308358-1&h=3204869214&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D797360686%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D1767839605%2526u%253Dhttp%25253A%25252F%25252Fwww.calcimedica.com%25252F%2526a%253Dwww.calcimedica.com%26a%3Dwww.calcimedica.com&a=www.calcimedica.com).\n\n**Forward-Looking Statements** This communication contains forward-looking statements which include, but are not limited to, CalciMedica's ongoing and planned clinical trials and the timing, design, expected patient enrollment thereof and the expected timing for the release of data from those trials, including its Phase 2b CARPO trial of Auxora for AP with accompanying SIRS, its ongoing Phase 1/2 CRSPA trial of Auxora in pediatric patients with AIPT, and its planned Phase 2 KOURAGE trial of Auxora in AKI with associated AHRF; the potential benefits of Auxora for the treatment of AP, AKI and AIPT; and the potential of CalciMedica's proprietary technology to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances. Risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption \"Risk Factors\" in CalciMedica's Annual Report on Form 10-K for the year ended December 31, 2023, and elsewhere in CalciMedica's subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at [www.sec.gov](https://c212.net/c/link/?t=0&l=en&o=4308358-1&h=4049631671&u=https%3A%2F%2Fwww.sec.gov%2F&a=www.sec.gov). These documents can be accessed on CalciMedica's web page at [ir.calcimedica.com/financials-filings/sec-filings](https://c212.net/c/link/?t=0&l=en&o=4308358-1&h=1311158087&u=https%3A%2F%2Fir.calcimedica.com%2Ffinancials-filings%2Fsec-filings&a=ir.calcimedica.com%2Ffinancials-filings%2Fsec-filings). The forward-looking statements contained herein are made as of the date hereof, and CalciMedica undertakes no obligation to update them after this date, except as required by law.\n\n**CalciMedica Contact:**\n\n**Investors and Media** Argot PartnersSarah Sutton/Kevin Murphycalcimedica@argotpartners.com(212) 600-1902\n\n![Cision](https://c212.net/c/img/favicon.png?sn=LA62392&sd=2024-11-20) View original content to download multimedia:<https://www.prnewswire.com/news-releases/calcimedica-announces-presentations-at-upcoming-medical-meetings-302312062.html>\n\nSOURCE CalciMedica, Inc.\n\nExplore More\n\n[ Our Technologies  ](https://calcimedica.com/technologies-pipeline/#our-technologies) [ Our Pipeline  ](https://calcimedica.com/technologies-pipeline/#our-pipeline) [ Our Story  ](https://calcimedica.com/about-us/#our-story) [ Our Team  ](https://calcimedica.com/about-us/#our-team)\n"
        },
        {
          "title": "CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates",
          "url": "https://ir.calcimedica.com/news-releases/news-release-details/calcimedica-reports-third-quarter-2024-financial-results-and-provides-clinical-corporate-updates",
          "content": "# Not Found\n\nThe requested URL \"/news-releases/news-release-details/calcimedica-reports-third-quarter-2024-financial-results-and-provides-clinical-corporate-updates\" was not found on this server.\n"
        },
        {
          "title": "CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer",
          "url": "https://ir.calcimedica.com/news-releases/news-release-details/calcimedica-strengthens-leadership-team-appointment-stephen",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![CalciMedica, Inc. Logo](/sites/g/files/knoqqb85191/themes/site/client_site/dist/images/Logo_Calcimedica_2023_June_500px.png) ](https://calcimedica.com \"CalciMedica\")\n\n  * [Technologies & Pipeline](https://calcimedica.com/technologies-pipeline/)\n  * [Pancreas](https://calcimedica.com/pancreas/)\n  * [Kidney](https://calcimedica.com/kidney/)\n  * [Lung](https://calcimedica.com/lung/)\n  * [About Us](https://calcimedica.com/about-us/)\n  * [Publications](https://calcimedica.com/publications/)\n  * [Investors + Media]()\n    * [Overview](/investor-relations)\n    * [News and Events](/news-events/press-releases)\n    * [Presentation](/presentations)\n    * [Corporate Governance](/corporate-governance/board-document-charters)\n    * [Stock Information](/stock-information/stock-quote-chart)\n    * [Financials and Filings](/financials-filings/sec-filings)\n    * [Resources](/resources/email-alerts)\n\n\n\n  * [Technologies & Pipeline](https://calcimedica.com/technologies-pipeline/)\n    * [Our Technologies](https://calcimedica.com/technologies-pipeline/#our-technologies)\n    * [Our Pipeline](https://calcimedica.com/technologies-pipeline/#our-pipeline)\n    * [Clinical Trials](https://calcimedica.com/technologies-pipeline/#clinical-trials)\n  * [Pancreas](https://calcimedica.com/pancreas/)\n    * [Acute Pancreatitis](https://calcimedica.com/pancreas/#acute-pancreatitis)\n      * [AP with SIRS](https://calcimedica.com/pancreas/#acute-pancreatitis-with-sirs)\n      * [Asparaginase-Induced Pancreatic Toxicity (AIPT)](https://calcimedica.com/pancreas/#asparaginase-induced-pancreatic-toxicity)\n    * [Chronic Pancreatitis](https://calcimedica.com/pancreas/#chronic-pancreatitis)\n  * [Kidney](https://calcimedica.com/kidney/)\n  * [Lung](https://calcimedica.com/lung/)\n\n\n\n  * [About Us](https://calcimedica.com/about-us/)\n  * [Publications](https://calcimedica.com/publications/)\n  * [Investors + Media]()\n    * [Overview](/investor-relations)\n    * [News and Events](/news-events/press-releases)\n    * [Presentation](/presentations)\n    * [Corporate Governance](/corporate-governance/board-document-charters)\n    * [Stock Information](/stock-information/stock-quote-chart)\n    * [Financials and Filings](/financials-filings/sec-filings)\n    * [Resources](/resources/email-alerts)\n  * [Contact Us](https://calcimedica.com/contact-us/)\n\n\n\n[ ](https://www.linkedin.com/company/calcimedica) [ ](https://twitter.com/calcimedicainc?lang=en)\n\nInvestor Relations \n\n#  Press Release \n\n[Press Releases](/news-events/press-releases)\n\n[IR Events & Presentations](/news-events/events-presentations)\n\n[Medical Events & Presentations](/news-events/medical-events-publications)\n\n## \n\nCalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer\n\nNovember 7, 2024\n\n[PDF Version](/node/8806/pdf)\n\nLA JOLLA, Calif., Nov. 7, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Stephen Bardin as Chief Financial Officer and the planned departure of Daniel Geffken, Interim Chief Financial Officer upon filing the Company's third quarter financial statements. Mr. Bardin brings extensive capital raising, corporate development, and strategic finance expertise to CalciMedica, having most recently served as CFO of atai Life Sciences.\n\n[ ![CalciMedica Logo \\(PRNewsfoto/CalciMedica, Inc.\\)](https://mma.prnewswire.com/media/685404/calcimedica_v3.jpg) ](https://mma.prnewswire.com/media/685404/calcimedica_v3.html)\n\n\"We are delighted to bring Stephen on board. He is a skilled and experienced biotechnology executive who will be invaluable to CalciMedica as we advance our clinical-stage pipeline,\" said Rachel Leheny Ph.D., Chief Executive Officer of CalciMedica. \"Stephen has been advising us on various strategic matters for several months and, most recently, was critical in executing our successful public financing last week. We look forward to his many future contributions as he now joins us full-time.\"\n\n\"CalciMedica has made impressive recent progress, delivering compelling clinical data for large and underserved patient populations,\" said Mr. Bardin. \"The CARPO Phase 2b data in patients with acute pancreatitis announced last month is promising and provides an optimistic readthrough to KOURAGE, CalciMedica's Phase 2 trial in acute kidney injury, which is expected to read out next year. I look forward to working more closely with the team as we advance AKI in the clinic and prepare for a Phase 3 program in AP.\"\n\nMr. Bardin most recently served as CFO of atai Life Sciences where he played a key role in the company's investor relations, business development, capital allocation, and financial operations activities. Prior to that, Mr. Bardin spent nearly three years at BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company with a broad pipeline of development programs, where he oversaw a broad range of finance activities and helped raise over $2B through a variety of financing transactions. Prior to that, Mr. Bardin held positions focused on finance, operations, and corporate development at Myovant Sciences, Inc., a subsidiary of Roivant at the time. He began his career advising life sciences companies at the Boston Consulting Group. Mr. Bardin holds an M.B.A. from the Stanford Graduate School of Business and graduated summa cum laude from Duke University with a B.S.E. in Biomedical Engineering.\n\n**About CalciMedica** CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – [NCT04681066](https://c212.net/c/link/?t=0&l=en&o=4296679-1&h=3539631264&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D2669185696%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D1699697110%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fstudy%25252FNCT04681066%25253Fterm%25253DNCT04681066%252526rank%25253D1%2526a%253DNCT04681066%26a%3DNCT04681066&a=NCT04681066)) in patients with acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS) and completed a Phase 2 trial (called CARDEA – [NCT04345614](https://c212.net/c/link/?t=0&l=en&o=4296679-1&h=4281906976&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D3152801644%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D1827566996%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4206849-1%252526h%25253D575802973%252526u%25253Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fstudy%2525252FNCT04345614%252526a%25253DNCT04345614%2526a%253DNCT04345614%26a%3DNCT04345614&a=NCT04345614)) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – [NCT06374797](https://c212.net/c/link/?t=0&l=en&o=4296679-1&h=3076565770&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D2144183414%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D78069076%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fstudy%25252FNCT06374797%25253Fterm%25253DKOURAGE%252526rank%25253D1%2526a%253DNCT06374797%26a%3DNCT06374797&a=NCT06374797)) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – [NCT04195347](https://c212.net/c/link/?t=0&l=en&o=4296679-1&h=2484423333&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D1916833438%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D2087960553%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4206849-1%252526h%25253D3497808046%252526u%25253Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fstudy%2525252FNCT04195347%2525253Fterm%2525253DNCT04195347%25252526rank%2525253D1%252526a%25253DNCT04195347%2526a%253DNCT04195347%26a%3DNCT04195347&a=NCT04195347)) in patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit [www.calcimedica.com](https://c212.net/c/link/?t=0&l=en&o=4296679-1&h=2619166060&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D797360686%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D1767839605%2526u%253Dhttp%25253A%25252F%25252Fwww.calcimedica.com%25252F%2526a%253Dwww.calcimedica.com%26a%3Dwww.calcimedica.com&a=www.calcimedica.com).\n\n**Forward-Looking Statements** Any statements in this press release about future expectations, plans and prospects for CalciMedica, including statements about CalciMedica's business strategy; the potential benefits of Auxora for the treatment of AP, AKI and AIPT; expected timing for the release of data from its clinical trials; the potential of CalciMedica's proprietary technology to provide therapeutic benefits in other life-threatening inflammatory and immunologic diseases; and other statements containing the words \"anticipate,\" \"believe,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"plan,\" \"predict,\" \"project,\" \"target,\" \"potential,\" \"will,\" \"would,\" \"could,\" \"should,\" \"continue,\" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: economic, business, competitive, and/or regulatory factors affecting the business of CalciMedica generally. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption \"Risk Factors\" in CalciMedica's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 and other filings CalciMedica makes with the SEC from time to time and available at [www.sec.gov](https://c212.net/c/link/?t=0&l=en&o=4296679-1&h=3531298949&u=https%3A%2F%2Fwww.sec.gov%2F&a=www.sec.gov). These documents can also be accessed on CalciMedica's web page at [ir.calcimedica.com/financials-filings/sec-filings](https://c212.net/c/link/?t=0&l=en&o=4296679-1&h=312752230&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4231092-1%26h%3D84595236%26u%3Dhttps%253A%252F%252Fir.calcimedica.com%252Ffinancials-filings%252Fsec-filings%26a%3Dir.calcimedica.com%252Ffinancials-filings%252Fsec-filings&a=ir.calcimedica.com%2Ffinancials-filings%2Fsec-filings). All forward-looking statements contained in this press release speak only as of the date on which they were made. CalciMedica undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.\n\n**CalciMedica Contact:**\n\n**Investors and Media** Argot PartnersSarah Sutton/Kevin Murphycalcimedica@argotpartners.com(212) 600-1902\n\n![Cision](https://c212.net/c/img/favicon.png?sn=LA50237&sd=2024-11-07) View original content to download multimedia:<https://www.prnewswire.com/news-releases/calcimedica-strengthens-leadership-team-with-appointment-of-stephen-bardin-as-chief-financial-officer-302298169.html>\n\nSOURCE CalciMedica, Inc.\n\nExplore More\n\n[ Our Technologies  ](https://calcimedica.com/technologies-pipeline/#our-technologies) [ Our Pipeline  ](https://calcimedica.com/technologies-pipeline/#our-pipeline) [ Our Story  ](https://calcimedica.com/about-us/#our-story) [ Our Team  ](https://calcimedica.com/about-us/#our-team)\n"
        },
        {
          "title": "CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference",
          "url": "https://ir.calcimedica.com/news-releases/news-release-details/calcimedica-participate-piper-sandler-36th-annual-healthcare",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![CalciMedica, Inc. Logo](/sites/g/files/knoqqb85191/themes/site/client_site/dist/images/Logo_Calcimedica_2023_June_500px.png) ](https://calcimedica.com \"CalciMedica\")\n\n  * [Technologies & Pipeline](https://calcimedica.com/technologies-pipeline/)\n  * [Pancreas](https://calcimedica.com/pancreas/)\n  * [Kidney](https://calcimedica.com/kidney/)\n  * [Lung](https://calcimedica.com/lung/)\n  * [About Us](https://calcimedica.com/about-us/)\n  * [Publications](https://calcimedica.com/publications/)\n  * [Investors + Media]()\n    * [Overview](/investor-relations)\n    * [News and Events](/news-events/press-releases)\n    * [Presentation](/presentations)\n    * [Corporate Governance](/corporate-governance/board-document-charters)\n    * [Stock Information](/stock-information/stock-quote-chart)\n    * [Financials and Filings](/financials-filings/sec-filings)\n    * [Resources](/resources/email-alerts)\n\n\n\n  * [Technologies & Pipeline](https://calcimedica.com/technologies-pipeline/)\n    * [Our Technologies](https://calcimedica.com/technologies-pipeline/#our-technologies)\n    * [Our Pipeline](https://calcimedica.com/technologies-pipeline/#our-pipeline)\n    * [Clinical Trials](https://calcimedica.com/technologies-pipeline/#clinical-trials)\n  * [Pancreas](https://calcimedica.com/pancreas/)\n    * [Acute Pancreatitis](https://calcimedica.com/pancreas/#acute-pancreatitis)\n      * [AP with SIRS](https://calcimedica.com/pancreas/#acute-pancreatitis-with-sirs)\n      * [Asparaginase-Induced Pancreatic Toxicity (AIPT)](https://calcimedica.com/pancreas/#asparaginase-induced-pancreatic-toxicity)\n    * [Chronic Pancreatitis](https://calcimedica.com/pancreas/#chronic-pancreatitis)\n  * [Kidney](https://calcimedica.com/kidney/)\n  * [Lung](https://calcimedica.com/lung/)\n\n\n\n  * [About Us](https://calcimedica.com/about-us/)\n  * [Publications](https://calcimedica.com/publications/)\n  * [Investors + Media]()\n    * [Overview](/investor-relations)\n    * [News and Events](/news-events/press-releases)\n    * [Presentation](/presentations)\n    * [Corporate Governance](/corporate-governance/board-document-charters)\n    * [Stock Information](/stock-information/stock-quote-chart)\n    * [Financials and Filings](/financials-filings/sec-filings)\n    * [Resources](/resources/email-alerts)\n  * [Contact Us](https://calcimedica.com/contact-us/)\n\n\n\n[ ](https://www.linkedin.com/company/calcimedica) [ ](https://twitter.com/calcimedicainc?lang=en)\n\nInvestor Relations \n\n#  Press Release \n\n[Press Releases](/news-events/press-releases)\n\n[IR Events & Presentations](/news-events/events-presentations)\n\n[Medical Events & Presentations](/news-events/medical-events-publications)\n\n## \n\nCalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference\n\nNovember 21, 2024\n\n[PDF Version](/node/8861/pdf)\n\nLA JOLLA, Calif., Nov. 21, 2024 /PRNewswire/ -- CalciMedica Inc. (\"CalciMedica\" or the \"Company\") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 9:10 a.m. ET/ 6:10 a.m. PT.\n\n[ ![CalciMedica Logo \\(PRNewsfoto/CalciMedica, Inc.\\)](https://mma.prnewswire.com/media/685404/calcimedica_v3.jpg) ](https://mma.prnewswire.com/media/685404/calcimedica_v3.html)\n\nA live webcast of the presentation can be accessed in the \"Upcoming Events\" section of CalciMedica's IR website at [https://ir.calcimedica.com/](https://c212.net/c/link/?t=0&l=en&o=4308689-1&h=817674686&u=https%3A%2F%2Fir.calcimedica.com%2F&a=https%3A%2F%2Fir.calcimedica.com%2F). A replay of the webcast will be archived on the Company's website for 90 days.\n\n**About CalciMedica**CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – [NCT04681066](https://c212.net/c/link/?t=0&l=en&o=4308689-1&h=3018797231&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D2669185696%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D1699697110%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fstudy%25252FNCT04681066%25253Fterm%25253DNCT04681066%252526rank%25253D1%2526a%253DNCT04681066%26a%3DNCT04681066&a=NCT04681066)) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and completed a Phase 2 trial (called CARDEA – [NCT04345614](https://c212.net/c/link/?t=0&l=en&o=4308689-1&h=2653813551&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D3152801644%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D1827566996%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4206849-1%252526h%25253D575802973%252526u%25253Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fstudy%2525252FNCT04345614%252526a%25253DNCT04345614%2526a%253DNCT04345614%26a%3DNCT04345614&a=NCT04345614)) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – [NCT06374797](https://c212.net/c/link/?t=0&l=en&o=4308689-1&h=3598051077&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D2144183414%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D78069076%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fstudy%25252FNCT06374797%25253Fterm%25253DKOURAGE%252526rank%25253D1%2526a%253DNCT06374797%26a%3DNCT06374797&a=NCT06374797)) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) and continuing to support the ongoing Phase 1/2 trial (called CRSPA – [NCT04195347](https://c212.net/c/link/?t=0&l=en&o=4308689-1&h=4110419626&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4243427-1%26h%3D1916833438%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4231092-1%2526h%253D2087960553%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4206849-1%252526h%25253D3497808046%252526u%25253Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fstudy%2525252FNCT04195347%2525253Fterm%2525253DNCT04195347%25252526rank%2525253D1%252526a%25253DNCT04195347%2526a%253DNCT04195347%26a%3DNCT04195347&a=NCT04195347)) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT). CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit [www.calcimedica.com](https://c212.net/c/link/?t=0&l=en&o=4308689-1&h=2629270301&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4231092-1%26h%3D1767839605%26u%3Dhttp%253A%252F%252Fwww.calcimedica.com%252F%26a%3Dwww.calcimedica.com&a=www.calcimedica.com).\n\n**CalciMedica Contact:**\n\n**Investors and Media** Argot PartnersSarah Sutton/Kevin Murphy _calcimedica@argotpartners.com_(212) 600-1902\n\n![Cision](https://c212.net/c/img/favicon.png?sn=LA62730&sd=2024-11-21) View original content to download multimedia:<https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-302312144.html>\n\nSOURCE CalciMedica, Inc.\n\nExplore More\n\n[ Our Technologies  ](https://calcimedica.com/technologies-pipeline/#our-technologies) [ Our Pipeline  ](https://calcimedica.com/technologies-pipeline/#our-pipeline) [ Our Story  ](https://calcimedica.com/about-us/#our-story) [ Our Team  ](https://calcimedica.com/about-us/#our-team)\n"
        }
      ]
    },
    {
      "section_name": "Featured Reports",
      "links": [
        {
          "title": "2023 Annual Report",
          "url": "https://ir.calcimedica.com/static-files/7d431c69-9102-48b9-bb3a-5d66c3a60ec9",
          "content": "\n"
        },
        {
          "title": "2022 Annual Report (Amendment)",
          "url": "https://ir.calcimedica.com/static-files/aa804b91-d05d-4ba3-af38-441c7a8d5fd6",
          "content": "\n"
        },
        {
          "title": "2022 Annual Report",
          "url": "https://ir.calcimedica.com/static-files/c8888763-a062-4cc2-89c8-6cc24aedc904",
          "content": "\n"
        }
      ]
    }
  ]
}